Educational reference
Lab work by peptide class
Clinicians often establish baselines before protocols and recheck markers during longer courses. This page groups commonly discussed laboratory concepts by mechanism class — not as orders, targets, or diagnoses.
Why lab work matters
Peptides interact with endocrine, metabolic, immune, and vascular systems in different ways. Labs do not “prove” subjective outcomes; they help contextualize safety signals (glycaemia, lipids, hepatic/renal function, inflammation) when a qualified professional judges testing appropriate.
GLP-1 receptor agonists
Examples: Semaglutide, Tirzepatide (dual GIP/GLP-1). Monitoring usually emphasises glycaemic control, lipids, renal/hepatic panels, and thyroid baseline because weight-loss peptides in this class have recognised metabolic effects in approved indications.
- HbA1c, fasting glucose, fasting insulin
- Lipid panel (LDL, HDL, triglycerides)
- Comprehensive metabolic panel
- Thyroid panel — TSH baseline
- Pancreatic enzymes (amylase / lipase) when symptoms suggest pancreatic concerns
Pepteligence entries: Semaglutide · Tirzepatide · Liraglutide · Retatrutide · Cagrilintide · Survodutide
GH-releasing peptides
Sermorelin, Tesamorelin, Ipamorelin, CJC-1295, Hexarelin — secretagogues that stimulate GH axis activity. IGF-1 is the downstream readout clinicians most often cite; glucose homeostasis and prolactin may merit attention with certain secretagogue combinations.
- IGF-1
- Fasting glucose, HbA1c
- IGFBP-3
- Prolactin — especially with GHRP-2 / GHRP-6–class agents
Pepteligence entries: Sermorelin · Tesamorelin · Ipamorelin · CJC-1295 · Hexarelin · GHRP-2 / GHRP-6 · MK-677
Healing peptides
BPC-157, TB-500, KPV, GHK-Cu — tissue-repair mechanisms are rarely tracked with peptide-specific biomarkers in community settings. General health baselines still help interpret illness or medication changes during a cycle.
- CBC — general health baseline
- CMP — electrolytes, renal and hepatic screening baseline
Mitochondrial / longevity peptides
MOTS-c, Epitalon, Humanin — discussion often ties to metabolic flexibility and inflammatory tone in research literature; human outcome biomarkers are not peptide-specific.
- Fasting glucose
- Insulin sensitivity–related markers when clinically indicated
- Inflammatory markers — e.g. hs-CRP where appropriate
Pepteligence entries: MOTS-c · Epitalon · Humanin · Pinealon · 5-Amino-1MQ
Neuropeptides
Selank, Semax, DSIP — no widely accepted peptide-specific serum panel in outpatient practice. Mental-health screening tools may be relevant when use parallels clinical anxiety, mood, or sleep complaints (clinician-directed).
- No peptide-specific monitoring in typical protocols
- Baseline mental-health screening if overlapping clinical concerns
Melanocortins
PT-141 (bremelanotide), Melanotan II — melanocortin agonists can affect vascular tone and pigmentation pathways. Blood pressure and cardiovascular baselines are commonly emphasised; MT-II discussions sometimes include skin and mole surveillance themes in clinical education (not self-directed diagnosis).
- Blood pressure monitoring
- Cardiovascular risk baseline as clinically appropriate
- Skin examination baseline — especially where MT-II–class tanning agonists are discussed
Pepteligence entries: PT-141
Melanotan II is not indexed as a separate peptide page at this time; class-level principles still apply when your clinician discusses melanocortin agonists.
Thymic peptides
Thymosin Alpha-1 — historically studied in immune modulation contexts. Immune panels may be discussed when aligning care with specific indications (ordering remains clinician-specific).
- Baseline immune-oriented labs when used alongside immune-related clinical goals
Pepteligence entries: Thymosin Alpha-1
Frequency
- Baseline — before or early at start when testing is agreed with your clinician
- Follow-up — often discussed at 4–8 weeks for metabolic markers when therapies affect glycaemia or weight
- Periodic monitoring — for longer cycles or when symptoms or comorbidities warrant reassessment